Abstract
Cabozantinib is a tyrosine kinase inhibitor approved in Europe for use in adults with aRCC who have received prior VEGF-targeted therapy, or are treatment naive with intermediate or poor risk. We report interim data on the real-world use of cabozantinib in patients with aRCC who have received prior VEGF-targeted therapy and nivolumab.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have